SILVERARC CAPITAL MANAGEMENT, LLC
CIK 0001816307 · BOSTON, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$962.2M
2026 Q2
Positions
73
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
42.3%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
ASND
ASCENDIS PHARMA A/S
5.7%
CELC
CELCUITY INC
5.4%
COGT
COGENT BIOSCIENCES INC
5.2%
URGN
UROGEN PHARMA LTD
5.0%
IMNM
IMMUNOME INC
4.4%
DNTH
DIANTHUS THERAPEUTICS INC
4.0%
RYTM
RHYTHM PHARMACEUTICALS INC
3.6%
ORKA
ORUKA THERAPEUTICS INC
3.5%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.